**Early Proteome Shift and Serum Bioactivity Precede Diesel Exhaust-induced Impairment of Cardiovascular Recovery in Spontaneously Hypertensive Rats**

Leslie C. Thompson, Jonathan H. Shannahan, Christina M. Perez, Najwa Haykal-Coates, Charly King, Mehdi S. Hazari, Jared M. Brown and Aimen K. Farraj

Single circulating factors are often investigated to explain air pollution-induced cardiovascular dysfunction, yet broader examinations of the identity and bioactivity of the entire circulating milieu remain understudied. The purpose of this study was to determine if exposure-induced cardiovascular dysfunction can be coupled with alterations in both serum bioactivity and the circulating proteome. Two cohorts of Spontaneously Hypertensive Rats (SHRs) were exposed to 150 or 500 μg/m^3 diesel exhaust (DE) or filtered air (FA). In Cohort 1, we collected serum 1 hour after exposure for proteomics analysis and bioactivity measurements in rat aortic endothelial cells (RAECs). In Cohort 2, we assessed left ventricular pressure (LVP) during stimulation and recovery from the sympathomimetic dobutamine HCl, one day after exposure. Serum from DE-exposed rats had significant changes in 66 serum proteins and caused decreased NOS activity and increased VCAM-1 expression in RAECs. While rats exposed to DE demonstrated increased heart rate at the start of LVP assessments, heart rate, systolic pressure, and double product fell below baseline in DE-exposed rats compared to FA during recovery from dobutamine, indicating dysregulation of post-exertional cardiovascular function. Taken together, a complex and bioactive circulating milieu may underlie air pollution-induced cardiovascular dysfunction.

The epidemiological and experimental databases are replete with evidence linking air-pollution-induced adverse cardiovascular health outcomes with increased levels of key circulating mediators. While these associations are strong, there is not yet enough research detailing the systemic events following air pollution exposure to accurately account for the reported cardiovascular health outcomes. The lack of available data stems in part from the complexity of systemic responses, which involve release of multiple mediators from injured or activated airway and alveolar epithelial cells, vascular endothelial cells, and/or infiltrating monocytes and neutrophils. Although some mechanistic studies have established roles for specific circulating markers, it is likely that air pollution causes more subtle shifts in the circulating milieu such that the consequent health effects cannot be completely stimulated by addition of any single circulating factor, or completely prevented by pharmacological blockade or gene knockout of said factor.

An emerging alternative applied in recent studies is the assessment of the bioactivity of serum or plasma collected from subjects after exposure. This bioactivity describes the potential for a suite of serum or plasma-bound factors to collectively alter cellular, tissue, and systemic organ function. For example, plasma collected from humans exposed to NO\textsubscript{2} altered gene expression patterns in naïve human coronary artery endothelial cells.

1Environmental Public Health Division, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA. 2School of Health Sciences, Purdue University, West Lafayette, IN, USA. 3College of the Mainland, Texas City, TX, USA. 4Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 5Leslie C. Thompson, Jonathan H. Shannahan, Jared M. Brown and Aimen K. Farraj contributed equally. Correspondence and requests for materials should be addressed to J.M.B. (email: jared.brown@ucdenver.edu) or A.K.F. (email: Farraj.aimen@epa.gov)
and serum collected from mice after exposure to mixed combustion emissions or wood smoke altered vascular reactivity of aortic rings collected from unexposed mice. These approaches are predicated on the assumption that in vivo responses will in part mirror those measured ex vivo. Furthermore, in vitro and ex vivo responses may provide clues relating to potential pathophysiology, as altered function in key cell types and tissues in vivo are hallmarks of cardiovascular disease. While changes in a subset of in vitro or ex vivo tissues may not definitively predict in vivo responses, the presence of a bioactive circulating milieu after exposure enhances the plausibility of systemic factors as drivers of end organ responses above associations with increases in systemic factors alone. To date, however, serum bioactivity studies have only examined functional responses in recipient cells/tissue and have not been combined with measures of cardiovascular function in donor subjects, nor has the content of circulating milieu been routinely interrogated by high content approaches.

The purpose of this study was to determine if serum bioactivity, alterations in the circulating milieu, and cardiovascular dysfunction all take place in Spontaneously Hypertensive Rats (SHRs) after exposure to the same air pollution source. SHRs, which we have previously determined to be more sensitive to diesel exhaust (DE) exposure than their normotensive counterparts, have well-documented high mean arterial pressure and left ventricular hypertrophy. We hypothesized that exposure-induced impairment in cardiovascular function will be preceded by an altered circulating milieu that is bioactive in vitro. To that end, using a two-cohort design, SHRs were exposed once to DE, a source linked to near-road adverse clinical outcomes and a major contributor to traffic-derived fine particulate matter (PM2.5) and nitrogen oxide (NOx) emissions. DE concentrations were targeted to 150 (DE150) or 500 (DE500) µg/m3 PM2.5 to mirror levels in congested urban areas at the low end and occupational exposure levels at the high end. In Cohort 1, bioactivity of serum from blood collected from SHRs 1 hour after the end of DE exposure was evaluated in rat aortic endothelial cells (RAECs), given that (1) systemic responses are triggered soon after exposure, (2) endothelial cell changes strongly correlate with later adverse systemic cardiovascular responses, and (3) endothelial cells interface directly with circulating factors (see experimental design in Fig. 1). Proteomic analysis was used to assess proteome-wide changes in the same serum samples as those used in the in vitro bioactivity assays. In Cohort 2, systemic cardiovascular function was interrogated in SHRs using a dobutamine stimulation and recovery challenge while measuring left ventricular pressure (LVP) by pressure catheterization. LVP Data were recorded during a 2-minute baseline period, followed by 2 minutes of i.v. dobutamine at 10 µg/kg/minute, and a 2-minute recovery period. After allowing heart rates to stabilize for about 10 minutes, LVP data were recorded for another 2-minute period, 2 minutes of i.v. dobutamine at 20 µg/kg/minute, and a final 2-minute recovery period.

Figure 1. Experimental Time Line and Procedures. In order to establish that serum bioactivity and proteome changes occur in subjects that later present with cardiovascular dysfunction, SHRs were exposed to diesel exhaust at 150 or 500 µg/m3 or filtered air, and then split into two cohorts. Blood samples were collected from Cohort 1 one hour following exposure. Serum was used for proteomics analysis, or applied to endothelial cells in vitro to test for bioactivity. Twenty-four hours after exposure, SHRs from Cohort 2 were used for in vivo assessment of systemic cardiovascular responses to dobutamine stimulation and recovery while measuring left ventricular pressure (LVP) by pressure catheterization. LVP Data were recorded during a 2-minute baseline period, followed by 2 minutes of i.v. dobutamine at 10 µg/kg/minute, and a 2-minute recovery period. After allowing heart rates to stabilize for about 10 minutes, LVP data were recorded for another 2-minute period, 2 minutes of i.v. dobutamine at 20 µg/kg/minute, and a final 2-minute recovery period.

The purpose of this study was to determine if serum bioactivity, alterations in the circulating milieu, and cardiovascular dysfunction all take place in Spontaneously Hypertensive Rats (SHRs) after exposure to the same air pollution source. SHRs, which we have previously determined to be more sensitive to diesel exhaust (DE) exposure than their normotensive counterparts, have well-documented high mean arterial pressure and left ventricular hypertrophy. We hypothesized that exposure-induced impairment in cardiovascular function will be preceded by an altered circulating milieu that is bioactive in vitro. To that end, using a two-cohort design, SHRs were exposed once to DE, a source linked to near-road adverse clinical outcomes and a major contributor to traffic-derived fine particulate matter (PM2.5) and nitrogen oxide (NOx) emissions. DE concentrations were targeted to 150 (DE150) or 500 (DE500) µg/m3 PM2.5 to mirror levels in congested urban areas at the low end and occupational exposure levels at the high end. In Cohort 1, bioactivity of serum from blood collected from SHRs 1 hour after the end of DE exposure was evaluated in rat aortic endothelial cells (RAECs), given that (1) systemic responses are triggered soon after exposure, (2) endothelial cell changes strongly correlate with later adverse systemic cardiovascular responses, and (3) endothelial cells interface directly with circulating factors (see experimental design in Fig. 1). Proteomic analysis was used to assess proteome-wide changes in the same serum samples as those used in the in vitro bioactivity assays. In Cohort 2, systemic cardiovascular function was interrogated in SHRs using a dobutamine stimulation and recovery challenge while measuring left ventricular pressure (LVP) by pressure catheterization, one day after exposure, consistent with the timing of DE-induced cardiovascular dysfunction reported in our previous study. Finally, we integrate the findings to speculate on potential systemic mechanisms that drove the in vivo responses and suggest future studies to further elucidate mechanisms of action.
DE150 group compared to the FA group at the end of the baseline period and at the max value during Dob10.

Double Product (mmHg window, along with the associated statistical comparisons. The key differences between Fig. 2 and Table 3 is that either the final baseline values, maximum dobutamine values, or final values at the end of the 2 minute recovery period following Dob20 when compared to both the FA group and the DE150 group. Also in Table 3, we reported in Table 3, the data for Mean Pressure were significantly lower in the DE500 group after the end of the recovery period (mean ± SD) or mean LVP began to drop in DE500 exposed SHRs during longer any significant differences between groups. We found no significant differences in LV peak systolic pressure (Fig. 2B) or mean LV pressure (Fig. 2C). However, mean LVP began to drop in DE500 exposed SHRs during exposure group are reported in Table 2.

Table 2. Animal Weight. Abbreviations – FA = Filtered Air, DE150 = 150µg/m³ diesel exhaust, DE500 = 500µg/m³ diesel exhaust, LVP = left ventricular pressure, BDL = below detectable limits, MMAD = mass median aerodynamic diameter, GSD = geometric standard deviation.

Table 1. Particle Characterization and Chamber Conditions. Abbreviations – FA = Filtered Air, DE150 = 150µg/m³ diesel exhaust, DE500 = 500µg/m³ diesel exhaust, LVP = left ventricular pressure, BDL = below detectable limits, MMAD = mass median aerodynamic diameter, GSD = geometric standard deviation.

Results

Diesel exhaust characteristics and overt toxicity. Exposure chamber atmosphere properties and diesel exhaust characteristics are reported in Table 1. Filtered air (FA) chambers contained approximately 1 µg/m³ of \(\text{PM}_{2.5}\) compared to around 206 µg/m³ for the DE150 chambers and 509 µg/m³ in DE500 chambers. Particle diameters ranged from approximately 120–140 nm. Exposure chamber CO was around 1 part per million (ppm) in the FA group, 4 ppm in the DE150 group, and 10 ppm in the DE500 group. NO concentrations registered 0.1 ppm in the FA group, 1.5 ppm in the DE150 group, and around 5 ppm in the DE500 group, with similar concentrations for NOx. Chamber NO2 levels were low, ranging from 0 to 0.6 ppm and SO2 levels were below detectable limits. Relative humidity ranged from 35–55%, temperature ranged from 20–24 °C, and O2 percent was around 21%. No animals showed any signs or symptoms of overt toxicity to diesel exhaust exposure. Subject body mass for each exposure group are reported in Table 2.

Left ventricular heart rate and pressure data. Data collected from LV pressure (LVP) measurements are presented in Fig. 2 and Table 3. When baseline recordings were made after urethane anesthesia and placement of the LV catheter, heart rate in SHRs exposed to DE500 (*for \(p < 0.05\)) and DE150 (†for \(p < 0.05\)) were elevated compared to the FA group (Fig. 2A). Once heart rates stabilized after the first dobutamine recovery, there were no longer any significant differences between groups. We found no significant differences in LV peak systolic pressure (Fig. 2B) or mean LV pressure (Fig. 2C). However, mean LVP began to drop in DE500 exposed SHRs during Dob20 and subsequent recovery period, diverging from the DE150 and FA controls, though never reaching statistical significance. In Table 3, data are presented as mean ± SD, and rather than instance data, are presented as either the final baseline values, maximum dobutamine values, or final values at the end of the 2 minute recovery window, along with the associated statistical comparisons. The key differences between Fig. 2 and Table 3 is that in Table 3, the data for Mean Pressure were significantly lower in the DE500 group after the end of the recovery period following Dob20 when compared to both the FA group and the DE150 group. Also in Table 3, we reported Double Product (mmHg ● HR in beats per minute i.e. BPM), which we found to be significantly elevated in the DE150 group compared to the FA group at the end of the baseline period and at the max value during Dob10.

Responsive versus stable left ventricular pressure endpoints. Also provided in Table 3 is a within group, repeated measures analysis of each LVP parameter to determine: a) which parameters demonstrated relative stability across the baseline, dobutamine, and recovery test periods; and b) which parameters demonstrated greater responsiveness (i.e. statistically significant increases or decreases from the immediately previous time point) to dobutamine challenge and recovery. These results are marked for statistical significance (\(p < 0.05\)) within each group using †, denoting a significant increase from the previous time point, or ‡, denoting a significant decrease from the previous time point. While all these functional parameters demonstrate some degree of

| Particle Characterization and Chamber Conditions | FA | DE150 | DE500 |
|-------------------------------------------------|----|-------|-------|
| PM\(_{2.5}\) \(\mu g/m^3\)                       | 1.1 ± 0.6 | 206 ± 30 | 509 ± 51 |
| MMAD \(nm\)                                      | — | 124 ± 9 | 139 ± 13 |
| GSD \(nm\)                                       | — | 1.7 ± 0.0 | 1.6 ± 0.0 |
| O\(_2\) \(\%\)                                    | 21.0 ± 0.1 | 20.9 ± 0.1 | 20.8 ± 0.1 |
| CO \(ppm\)                                       | 1.0 ± 0.8 | 4.1 ± 0.0 | 10.1 ± 1.2 |
| SO\(_2\) \(ppm\)                                 | — | BDL | BDL |
| NO \(ppm\)                                       | 0.1 ± 0.0 | 1.5 ± 0.1 | 4.9 ± 0.5 |
| NO\(_2\) \(ppm\)                                 | 0.0 ± 0.1 | 0.1 ± 0.0 | 0.6 ± 0.1 |
| NOx \(ppm\)                                      | 0.2 ± 0.1 | 1.6 ± 0.2 | 5.5 ± 0.6 |
| Temperature \(°C\)                               | 20.5 ± 0.4 | 24.3 ± 0.0 | 24.0 ± 1.0 |
| Relative Humidity \(\%\)                         | 54.3 ± 4.5 | 35.2 ± 0.2 | 38.7 ± 4.1 |

Table 1. Particle Characterization and Chamber Conditions. Abbreviations – FA = Filtered Air, DE150 = 150µg/m³ diesel exhaust, DE500 = 500µg/m³ diesel exhaust, LVP = left ventricular pressure, BDL = below detectable limits, MMAD = mass median aerodynamic diameter, GSD = geometric standard deviation.

| Animal Weight | FA | DE150 | DE500 |
|---------------|----|-------|-------|
| Mass \(g\)    | 309 ± 10 | 342 ± 27 | 312 ± 10 |
| Serum Cohort  | 308 ± 13 | 334 ± 41 | 307 ± 22 |
| LVP Cohort    | — | — | — |

Table 2. Animal Weight. Abbreviations – FA = Filtered Air, DE150 = 150µg/m³ diesel exhaust, DE500 = 500µg/m³ diesel exhaust, LVP = left ventricular pressure.
responsiveness through baseline, dobutamine challenge, and recovery, the degree of change in some parameters should be more physiologically responsive to dobutamine/recovery (e.g., heart rate, peak positive pressure change i.e. +dP/dT, and double product) and some need to remain relatively stable in response to dobutamine and recovery (e.g., peak systolic pressure, end diastolic pressure, and mean pressure). Nonetheless, a few parameters that were responsive in the FA group showed less responsiveness in one or both DE group(s) and vice versa, i.e., parameters that were stable in the FA group showed less stability in one or both DE group(s). For example, heart rate was responsive in the FA group and DE500 group after 2 minutes of recovery following Dob20, but peak dP/dT showed to be less responsiveness in the DE500 group. Peak systolic pressure in the LV showed statistical stability in the FA group but showed less stability in the DE150 and DE500 groups during the Dob20 and during recovery after Dob20. Mean LVP pressure was also stable in the FA and DE500 groups but showed less stability in the DE150 group during Dob20.

Evidence of decreased postexertional heart function. We went on to compare the differences in peak values from the first and second dobutamine challenges, as well as the differences in recovery values collected 2 minutes after the end of the first and second dobutamine challenges. Results of this analysis are presented in Fig. 3. We found no differences between groups when comparing the differences in peak heart rate (Fig. 3A), LV peak systolic pressure (Fig. 3C), and peak double product (Fig. 3E) derived by multiplying heart rate (BPM) by systolic pressure (mmHg). However, when comparing the final recovery values taken 2 minutes after the end of recovery following Dob20, peak dP/dT was responsive in the FA group and DE150 group after 2 minutes of recovery following Dob20, but peak dP/dT showed to be less responsiveness in the DE500 group. Peak systolic pressure in the LV showed statistical stability in the FA group but showed less stability in the DE150 and DE500 groups during the Dob20 and during recovery after Dob20. Mean LVP pressure was also stable in the FA and DE500 groups but showed less stability in the DE150 group during Dob20.

Evidence of decreased postexertional heart function. We went on to compare the differences in peak values from the first and second dobutamine challenges, as well as the differences in recovery values collected 2 minutes after the end of the first and second dobutamine challenges. Results of this analysis are presented in Fig. 3. We found no differences between groups when comparing the differences in peak heart rate (Fig. 3A), LV peak systolic pressure (Fig. 3C), and peak double product (Fig. 3E) derived by multiplying heart rate (BPM) by systolic pressure (mmHg). However, when comparing the final recovery values taken 2 minutes after the end of
Table 3. Left Ventricular Pressure Parameters by Time Period. Notes: FA = filtered air; DE150 = 150 µg/m³ diesel exhaust; DE500 = 500 µg/m³ diesel exhaust; Dob10 Max Val = maximum value during infusion with 10 µg/kg/min dobutamine; After 2 min Rec = value after 2 minutes of recovery; Dob20 Max Val = maximum value during infusion with 20 µg/kg/min dobutamine; HR = heart rate; BPM = beats per minute; dP/dT = change in pressure per change in time; Peak SP = peak systolic pressure; EDP = end diastolic pressure; Symbols for p < 0.05: *vs. FA; †vs. DE150; ‡ increase vs previous data point; ↓ = decrease vs. previous data point.

The first and second dobutamine challenges, heart rate demonstrated a significant decreasing linear trend (by ANOVA) from the FA group, to DE150, and then to DE500 (Fig. 3B). The comparison of final recovery values for LV peak systolic pressure also showed a significant decreasing linear trend across the 3 groups and the DE500 value was significantly lower than that of the FA group (Fig. 3D). Similarly, comparison of the double product values between the two recovery periods showed a significant decreasing linear trend and the value for the DE500 group was significantly lower than the FA group (Fig. 3F).

Endothelial bioactivity of serum. The results of in vitro treatment of rat aortic endothelial cells (RAECs) with serum collected from FA or DE exposed SHRs is presented in Fig. 4. Twenty-four hours after treatment of RAECs with serum, cell viability showed a significant decreasing linear trend (‡) with DE concentration but were not significantly different between groups by one-way ANOVA (Fig. 4A). However, nitric oxide synthase (NOS) activity was significantly decreased in RAECs treated with DE150 (*) or DE500 (*) serum for 24 hours as compared to FA serum (Fig. 4B), and a decreasing linear trend (‡). No statistically significant differences were found in Alox15, Tbxas, Edn1, Ho1, Il33, Nos3, Icam1, Vcam1, Cxcl2, and Il6 mRNA expression in RAECs after 24 hour treatment with serum collected from exposed SHRs (see Supplemental Table S1). However, as shown in Supplemental Fig. S1A, Alox15 expression was >2-fold downregulated relative to Alox15/Gapdh ratio in the FA and DE150 groups. In follow-up we tested 15-HEET concentrations in serum to see if a negative feedback system may explain any down-regulation of Alox15 and found no differences between exposure groups (Supplemental Fig. S1B). After 3 hours of serum exposure, RAECs showed a significant increasing linear trend (‡) for cell surface vascular cell adhesion molecule-1 (VCAM-1) expression, which was significantly increased with serum treatment from DE500 exposed SHRs vs. treatment with serum from DE150 (†) exposed SHRs (Fig. 4C).

Serum proteomics profiling. The analysis results of serum proteomics is displayed in Tables 4 and 5, and Fig. 5. The analysis of serum peptides uncovered 4116 total peptides, 3827 peptides were present in all replicates in at least one condition, e.g. FA, DE150, or DE500. Significance and fold change filters (p < 0.05; >20% change) were used to determine if any peptides were different between groups. A one-way ANOVA utilizing Storey bootstrapping for multiple testing correction identified 375 peptides that were significantly altered (p < 0.05), 186 of which showed a greater than 20% change between FA and DE500. The clustering pattern was confirmed by unsupervised hierarchical clustering of averaged replicate data (Fig. 5). Peptides were used to identify alterations in proteins following exposure to DE150, DE500, or FA (Table 4). Concentration-dependent alterations
were observed in the number of proteins altered following exposure with most proteins being down-regulated (Table 4).

Individual proteins were compared across groups to evaluate alterations due to DE exposures (Table 5). Many proteins altered following DE exposure were found to be related to the acute phase response, including those related to activation of the complement system (complement C1q subcomponent subunits A, B, and C, C4b-binding protein alpha chain, decorin, vitamin K-dependent protein S, and mannose-binding protein A), coagulation (factor IX), iron homeostasis (ceruloplasmin, serotransferrin, and hemoglobin subunits alpha ½, beta 1, and beta 2), serine protease inhibitors (serine protease inhibitor A3N A3L, and A3K), and immune activation (interleukin-1 receptor accessory protein, forkahed box protein, receptor-type tyrosine-protein phosphatase V, Ig kappa chain C region, A allele, Ig gamma-2A chain C region, and DNAJ homolog subfamily C member 27; Table 5). Other DE-modified proteins were involved in lipid metabolism (oxidized low-density

Figure 3. Comparison of Dobutamine Periods and Recovery Stability. We tested the differences between maximal responses between the two dobutamine periods and the stability of functional parameters during the recovery period. When we compared peak responses between Dob10 and Dob20 we found no differences between exposure groups for heart rate (A), systolic pressure (C), and Double Product (E). However, comparison of the values at the end of the recovery periods showed a decreasing linear trend (ANOVA) with DE concentration, with recovery 2 being lower than recovery 1 for heart rate (B), systolic pressure (D), and double product (F). Low values for recovery 2 vs. recovery 1 were significantly lower for DE500 than the FA group for systolic pressure (D) and double product (F). *For p < 0.05 DE500 vs. FA by one-way ANOVA and Tukey’s post-test. ‡for p < 0.05 linear trend analysis ANOVA. n = 5–6.
lipoprotein receptor 1, apolipoprotein C-IV, and apolipoprotein C-III) as well as vascular permeability and tone (angiopoietin-2, Rho-associated protein kinase 1, T-kininogen, adenylate cyclase type 6, and profiling-1; Table 5).

Discussion

This study provides evidence indicating that diesel exhaust (DE) exposure impacts serum bioactivity, the circulating proteome, and cardiovascular function in SHRs. More specifically, relative to SHRs exposed to filtered air, a single 4-hour diesel exhaust (DE) inhalation exposure resulted in impairment of postexertional cardiovascular function one day later during recovery from pharmacological challenge with the sympathomimetic dobutamine.
The interrogation of serum collected from similarly-exposed SHRs 1-hour after exposure revealed enhanced bioactivity of serum in naïve rat aortic endothelial cells, predominantly by decreasing activity of NOS. Proteomic assessment of this serum indicated significant changes in the levels of 66 proteins related to vascular function, lipid metabolism, iron homeostasis, redox regulation, and the acute phase response. These findings indicate the need for more holistic examinations of the circulating milieu in air pollution-induced adverse cardiovascular health outcomes.

First, the exposure to DE in SHRs did lead to impairment of cardiovascular responses to dobutamine stimulation and recovery. The first indication of cardiovascular impact appeared after the onset of LVP assessments in anesthetized SHRs. Heart rates in both DE groups were elevated prior to administration of any dobutamine. Though we did not assess autonomic activity in the current study, this finding supports our previous study showing that DE inhalation in SHRs promotes sympathetic activation. Interestingly, heart rates in the DE groups appeared to reset toward the level of the FA group after the first dobutamine challenge. Normally sympathetic stimulation (i.e. epinephrine/norepinephrine release) increases heart rate by increasing cellular cyclic AMP levels but it has been reported that dobutamine antagonizes in vitro production of cyclic AMP when administered with epinephrine. The next indication of cardiovascular impact was that recovery values for HR, LVP, peak systolic pressure, and double product did not return to a stable baseline after the second of two dobutamine challenges. Impaired recovery after dobutamine in DE-exposed SHRs is consistent with impaired post-exercise recovery of cardiac function in humans exposed to air pollution, which included double product, a correlate of oxygen uptake by the myocardium during exercise. Low systolic pressure after exercise challenge (i.e. postexertional hypotension), often manifesting as syncope, is linked to increased risk for cardiac events. Additionally, the absence of a reflex increase in heart rate in response to postexercise hypotension suggests impairment of arterial baroreflex control of heart rate. Although we did not measure baroreflex responses in the present study, the loss of baroreflex sensitivity would be consistent with our previous findings that showed that acrolein inhalation reduced baroreceptor sensitivity in the same hypertensive rat strain used in the present study. While the precise biological mechanisms that mediate these integrated cardiovascular responses to DE exposure are unclear, our proteomics assessment identified alterations in proteins related to vascular tone, smooth muscle contraction, and lipid metabolism, iron homeostasis, redox regulation, and the acute phase response. These findings indicate the bioactivity of serum in naïve rat aortic endothelial cells, predominantly by decreasing activity of NOS. Proteomic assessment of this serum indicated significant changes in the levels of 66 proteins related to vascular function, lipid metabolism, iron homeostasis, redox regulation, and the acute phase response. These findings indicate the need for more holistic examinations of the circulating milieu in air pollution-induced adverse cardiovascular health outcomes.

Second, DE inhalation produced bioactive serum in blood collected from SHRs one hour after exposure. While the novelty of our study is the connection of all 3 events, i.e., changes in cardiovascular function, serum bioactivity, and serum proteome following DE exposure, it is important to note that the serum bioactivity in our study parallels that of other studies, specifically the decrease in NOS activity and increased VCAM-1 expression. This is also important because postexercise cardiovascular recovery, as we have just described, requires complex, integrated responses between the cardiovascular system and autonomic nervous system, as well as a healthy, responsive population of vascular endothelial cells. In this regard, NOS is a key indicator of vascular endothelial cell function and often investigated following DE exposure. For example, DE exposure has been linked to vascular endothelial NOS dysfunction after in vivo inhalation and by direct action of the DE particle components 1,2-naphthoquinone and phenanthraquinone when added to ex vivo isolated aortic segments. Moreover, loss of nitric oxide availability likely promotes increased VCAM-1 expression, which leads to our in vitro findings in VCAM-1. We found that stimulation of RAECs in vitro with serum collected from SHRs exposed to DE500 caused upregulation of VCAM-1 expression when compared to treatment with serum collected from DE150. Although the difference in VCAM-1 expression between RAECs treated with serum from FA and RAECs treated with serum from DE500 was not statistically significant with a one-way ANOVA (P = 0.06), it was different from DE150 (see † in Fig. 4C). Also, analysis of all 3 means resulted in a statistically significant positive linear trend (see ‡ in Fig. 4C). This discrepancy could be due to timing as the VCAM assessment was after a 3-hour exposure to serum whereas the NOS data was derived after a 24-hour exposure. In any case, our finding is consistent with a report indicating upregulation of VCAM-1 in primary human coronary artery endothelial cells after 24-hour treatment with human plasma collected from DE-exposed volunteers. Cell culture media from DE particle-exposed airway epithelial cells produced similar increases in VCAM-1 in endothelial cells treated in vitro. Circulating VCAM-1 was also reported to be slightly (but not significantly) elevated in a controlled human study after DE exposure. RAEC viability after treatment with serum from DE-exposed SHRs was not significantly different from cells treated with serum from FA and DE150 groups, but there was a significant trend downward as DE exposure concentration increased, which could explain, in part, the presence of many intracellular proteins found in our proteomics data. Collectively, the in vitro findings point to a change in the endothelial

Table 4. Total Proteins Altered with DE Exposure. Abbreviations: FA = filtered air; DE150 = 150 µg/m³ diesel exhaust; DE500 = 500 µg/m³ diesel exhaust.

| Total Proteins Altered with DE Exposure | DE500 vs. FA | DE150 vs. FA | DE500 vs. DE150 |
|----------------------------------------|--------------|--------------|-----------------|
| Proteins                               | 46           | 23           | 74              |
| Up-Regulated                           | 16           | 5            | 35              |
| Down-Regulated                         | 30           | 18           | 39              |

Threshold determined by p < 0.05
| Protein Name                                      | p-value | Percent Change | DE150 vs. FA | DE500 vs. FA | DE500 vs. DE150 | Peptide |
|--------------------------------------------------|---------|----------------|--------------|--------------|-----------------|---------|
| Coagulation factor IX (Fragment)                 | 1.04e-5 | −0.61          | −13.21       | −12.52       | 4               |         |
| Heat shock 70 kDa protein 4                       | 1.17e-5 | 4.85           | −15.58       | −21.18       | 1               |         |
| Leucine-rich repeat-containing protein 8C         | 1.92e-5 | −5.69          | −36.09       | −28.77       | 1               |         |
| Complement C1q subcomponent subunit A            | 2.44e-4 | −3.00          | −25.56       | −21.90       | 1               |         |
| Phosphatidylinositol-5-phosphate 4-kinase type-2 γ| 4.50e-4 | −4.16          | −30.33       | −25.13       | 1               |         |
| Large proline-rich protein BAT3                   | 5.58e-4 | −3.10          | 24.54        | 28.40        | 1               |         |
| Apolipoprotein C-IV                              | 6.57e-4 | −29.10         | 7.35         | 38.59        | 1               |         |
| Oxidized low-density lipoprotein receptor 1       | 1.07e-3 | −9.00          | −2.20e5      | −2.02e5      | 1               |         |
| Protein kinase C8                                 | 1.21e-3 | −23.03         | −7.44        | 14.51        | 1               |         |
| Serine protease inhibitor A3N                     | 1.31e-3 | −8.21          | −18.47       | −9.48        | 23              |         |
| Rho-related GTP binding protein RhoE              | 1.32e-3 | 0.32           | 16.22        | 15.86        | 1               |         |
| Adenylate cyclase 6                               | 1.54e-3 | −3.39          | 31.40        | 35.86        | 1               |         |
| Glutathione peroxidase 3                         | 2.13e-3 | −10.42         | −2.65        | 7.57         | 7               |         |
| Selenoprotein P                                   | 2.57e-3 | −5.89          | −20.12       | −13.44       | 3               |         |
| Ig κ chain C region, A allele                    | 2.79e-3 | 62.41          | −62.72       | −164.27      | 2               |         |
| Apolipoprotein A-II                              | 2.97e-3 | −24.17         | −5.06        | 18.20        | 5               |         |
| Calcinurin subunit B type 1                      | 3.06e-3 | −5.43          | 11.21        | 17.25        | 1               |         |
| Serotransferrin                                   | 3.38e-3 | −12.53         | 18.75        | 33.64        | 2               |         |
| Complement C1q subcomponent subunit C            | 3.42e-3 | −0.42          | −20.17       | −19.67       | 3               |         |
| PHD finger protein 10                             | 3.56e-3 | 5.92           | −14.07       | −20.82       | 1               |         |
| Sodium- and chloride-dependent glycine transporter 1 | 3.64e-3 | 0.44           | 17.22        | 16.70        | 1               |         |
| Centromere protein T                             | 3.72e-3 | −0.76          | 11.30        | 12.15        | 1               |         |
| Angiopoietin-2                                    | 4.31e-3 | 5.16           | −24.17       | −30.57       | 1               |         |
| Transmembrane protein 106 A                      | 4.45e-3 | 7.28           | −4.48        | −12.08       | 1               |         |
| Complement C1q subcomponent subunit B            | 4.59e-3 | −2.61          | −15.72       | −12.78       | 2               |         |
| Receptor-type tyrosine-protein phosphatase epsilon| 5.16e-3 | −47.16         | 22.09        | 79.67        | 1               |         |
| Ig gamma-2A chain C region                        | 5.73e-3 | 73.50          | −46.42       | −154.05      | 2               |         |
| Hemoglobin subunit 3-2                            | 6.00e-3 | 95.66          | 103.09       | 3.80         | 3               |         |
| Hemoglobin subunit α-1/2                          | 6.15e-3 | 94.13          | 102.91       | 4.52         | 10              |         |
| Hemoglobin subunit 3-1                            | 7.09e-3 | 93.76          | 95.63        | 0.96         | 14              |         |
| Ceruloplasmin                                     | 7.92e-3 | 3.76           | −18.13       | −22.57       | 46              |         |
| Dual homolog subfamily C member 27                | 8.03e-3 | 13.71          | −14.14       | −29.79       | 1               |         |
| Forkhead box protein J1                           | 8.43e-3 | −4.93          | −32.51       | −26.29       | 1               |         |
| Mannose-binding protein A                         | 9.09e-3 | −12.41         | −15.45       | −2.70        | 2               |         |
| E3 ubiquitin-protein ligase UBR4                  | 9.18e-3 | −4.31          | 11.72        | 16.53        | 1               |         |
| C4b-binding protein α chain                       | 1.00e-2 | −34.84         | 41.77        | 91.17        | 7               |         |
| Apolipoprotein C-III                              | 1.02e-2 | −12.21         | 13.47        | 27.33        | 4               |         |
| Rho-associated protein kinase 1                   | 1.31e-2 | 8.59           | −20.99       | −31.38       | 2               |         |
| Ephrin type-A receptor 3                          | 1.32e-2 | 0.68           | −10.28       | −11.03       | 1               |         |
| Tetra tricopeptide repeat protein GNN             | 1.35e-2 | −0.96          | 18.08        | 19.22        | 2               |         |
| Serine protease inhibitor A3L                     | 1.38e-2 | 7.38           | −21.69       | −30.67       | 5               |         |
| Tetra tricopeptide repeat protein 35              | 1.39e-2 | 1.19           | −18.98       | −20.40       | 1               |         |
| RAG family molecular chaperone regulator 5        | 1.44e-2 | −3.47          | −21.40       | −25.61       | 1               |         |
| Vomeronasal type-1 receptor A13                   | 1.44e-2 | 0.66           | 13.34        | 12.60        | 1               |         |
| Serine protease inhibitor A5K                     | 1.59e-2 | 7.13           | −17.28       | −25.65       | 29              |         |
| Uncharacterized protein C19orf44 homolog           | 1.62e-2 | 4.78           | 11.47        | 6.38         | 1               |         |
| Peroxisomal acyl-coenzyme A oxidase 2             | 1.64e-2 | 4.45           | 17.59        | 12.58        | 1               |         |
| Interleukin-1 receptor accessory protein          | 1.66e-2 | 3.00           | −20.06       | −23.66       | 1               |         |
| Plectin                                           | 1.82e-2 | 6.18           | −16.21       | −23.39       | 2               |         |
| Parvalbumin alpha                                 | 1.94e-2 | −2.67          | 8.68         | 11.59        | 1               |         |
| Transcription activator BRG1                      | 2.02e-2 | 3.50           | −8.17        | −11.96       | 1               |         |
| Receptor-type tyrosine-protein phosphatase V      | 2.16e-2 | −0.59          | −20.54       | −19.84       | 1               |         |
| Interferon-induced, double-strand RNA-activated protein kinase | 2.18e-2 | −0.50 | 10.28 | 10.83 | 1 |
| T-kininogen 1                                     | 2.24e-2 | 4.66           | −21.78       | −27.45       | 19              |         |
| Scm-like with four MBT domains protein 1          | 2.28e-2 | −6.14          | 3.77         | 10.14        | 1               |         |

Continued
bioactivity of serum after exposure to diesel exhaust indicating the potential to alter vascular tissue function \textit{in vivo}. We suspect that loss of NOS activity and VCAM-1 induction following \textit{in vitro} stimulation with serum from DE exposed SHRs demonstrates the potential for loss of precision responsiveness needed for optimal postexertional cardiovascular recovery \textit{in vivo}.

Lastly, alterations in serum proteome identified one hour after DE exposure, especially those related to oxidative stress, could explain the modified endothelial and cardiovascular function. These include proteins involved in intracellular signaling in the cardiovascular system associated with pathophysiologic responses, e.g., adenylate cyclase, calcineurin, and RhoE\textsuperscript{39,40}. The presence of these proteins in the serum may reflect cytotoxicity in vascular tissue caused by DE exposure, as takes place with oxidative stress\textsuperscript{41}. Of the factors that increased in serum, hemoglobin subunits $\alpha$-1/2, $\beta$-1, and $\beta$-2 did so to the highest extent in both the DE\textsubscript{500} and DE\textsubscript{150} groups. Free hemoglobin undergoes autoxidation as it becomes deoxygenated and as hemoglobin tetramers breakdown into dimers\textsuperscript{42}. Circulating free hemoglobin and associated reactive oxygen species tend to interfere with essential vascular functions by sequestering NO and transforming it to peroxynitrite\textsuperscript{43}, which could be made worse following DE exposure. Conversely, heat shock protein 70 was decreased in serum from DE\textsubscript{500} exposed SHRs. This stands in contrast to a report stating that heat shock protein 70 increases in the plasma of ApoE knockout mice after chronic exposure to DE. Heat shock proteins can function as chaperone proteins that help cells cope with oxidative stress and are generally regarded as protective\textsuperscript{44}. However, in certain conditions such as metabolic syndrome, heat shock protein 70 (hsp70) decreases in the circulation\textsuperscript{45}. Furthermore, heat shock protein 70 can be cleared or taken up by macrophages and other antigen presenting cells when it is complexed to damaged proteins\textsuperscript{46,47}. While the net ramifications of all the proteins that increased or decreased after DE exposure remain unknown, it seems likely the alterations in the circulating proteome after DE exposure may set the stage for an array of negative impacts in the cardiovascular system.

In addition to the proteomic findings mentioned above, one key group of proteins consistently diminished by DE exposure are those related to the acute phase response. For example, interleukin-1 receptor accessory protein was decreased following DE\textsubscript{500} exposure. This protein is involved in interleukin-1 signaling that initiates the systemic acute phase response\textsuperscript{48}, including complement system activation and changes in coagulation, proteases,
iron levels, and immune system homeostasis. Along those lines, we also found that DE exposure reduced complement system proteins C1q subunits A, B, and C, and mannose-binding protein-A. C1q is a component of the C1 enzyme complex directly involved in complement system activation, which has been reported following DE exposure. Some protease inhibitors A3N, A3K, and A3L were also reduced following exposure to DE500. These findings are consistent with a previous report detailing a lack of evidence for acute phase response in the livers of mice following DE exposure at even higher concentrations than used in our study. The absence or impairment of the acute phase response following DE inhalation may lead to a period of heightened susceptibility to infection, as is evident with malnutrition-related decreases in acute phase response. In fact, increases in ambient PM$_{2.5}$ have recently been linked to increased incidence of acute lower respiratory infections. Thus, these reductions in acute phase response elements support the idea that changes in circulating factors after air pollution exposure may diminish the capacity of an individual to handle subsequent physiological stressors.

Some limitations should be considered with this study. First, SHRs were anesthetized with sodium pentobarbital, so residual anesthetic likely remained in the serum used to treat RAECs given that the half-life of sodium pentobarbital is approximately 4 hours. Nonetheless, an anesthetic was required for high volume blood collection and alternative anesthetics are burdened by their own limitations. For example, isoflurane has been shown to interfere with endothelium-dependent vasodilation and ketamine/xylazine and trimbromoethanol have been shown to induce endothelial injury more rapidly than sodium pentobarbital. Additionally, the SHRs used as a model in this study collectively showed unexpected reductions in absolute value for peak diastolic dp/dt during dobutamine challenge in all groups. In our study, dobutamine infusion resulted in reduced absolute value for diastolic dp/dt in all groups. These findings may be explained by slower Ca$^{2+}$ uptake in myocytes in SHRs such that excess myocyte free Ca$^{2+}$ during dobutamine challenge could have impaired cardiac lusitropy. Another important note is that we have only examined the serum proteome and the resulting endothelial bioactivity at a single time point after exposure. It remains unclear when peak shifts in the proteome after DE exposure occur, as changes in circulating factors are likely to be dynamic over time. This limitation may be best demonstrated by the fact that decreased NOS activity, which may in fact be decreased NOS expression, in the DE150 group was not matched by an increase in VCAM-1 expression as was seen in the DE500 group. Furthermore, the RT-PCR data for endothelin-1 and VCAM were not in agreement with the NOS activity and VCAM protein data. While the precise reasons for these discrepancies are unclear, mRNA, protein expression, and protein activity do not always change to the same extent within a single window of time, especially when varying stimulated doses, in this case of DE, may impact to varying degrees the expression/degradation rate of mRNA and protein, and even post-translational protein modifications. Different stimuli may also initiate different rates of down-regulation followed by upregulation and vice versa. In the case of VCAM-1, NOS-independent pathways may have altered VCAM-1 expression. Finally, while a focus on systemic inflammation as a driver of the effects in this study may be plausible, specific markers of inflammation were not measured, thus limiting any linkage of the cardiovascular and endothelial responses to specific inflammatory pathways. We opted to carry out a global proteomic assessment because of the uncertainty in the identification of the factors that may be driving such responses.

This study lays the groundwork for more mechanistic lines of inquiry in the future. For example, keying in on specific indicators of inflammation like interleukins 1 and 10, tumor necrosis factor, and C-reactive protein. Uncovering the time course of changes in VCAM-1 and NOS (e.g. NOS3 vs. NOS2 and expression vs. activity) may be very informative for understanding how DE exposure results in systemic cardiovascular dysfunction in SHRs. Utilizing the adoptive transfer approach on isolated aortic segments collected from naïve SHRs to test changes in vascular function may also be informative. Moreover, utilizing the adoptive transfer of serum from exposed rats to naïve rats to see if the systemic cardiovascular function can be replicated would be highly advantageous, provided complicating factors like how much serum needs to be transferred to successfully transfer and initiate the progression of cardiovascular dysfunction are properly addressed. Finally, exploring sex-specific responses may also help elucidate mechanism and issues of susceptibility.

In conclusion, this study enhances plausibility of the hypothesis that an array of changes in circulating factors after DE exposure can, in turn, precipitate measurable alterations in systemic cardiovascular function. While alterations in the circulating milieu were indeed complex, the findings in fact point to perturbation of various systemic pathways, including vascular function, lipid metabolism, iron homeostasis, redox regulation, and the acute phase response. Thus, it would be worthwhile to explore the impacts of antagonism of these pathways on the in vivo cardiovascular responses to diesel exhaust to definitively assign causality in future studies. Moreover, we provide evidence in the same model that air pollution-induced impairment of systemic cardiovascular function occurs in conjunction with changes in the circulating proteome and serum bioactivity. These findings are consistent with much of the data in epidemiological and clinical exposure studies that associate changes in systemic markers with adverse cardiovascular health outcomes. Still, the biological responses appear to consist of concurrent changes in systemic circulating factors and autonomic nervous system responses, which point to the complexity of air pollution health effects.

Materials and Methods

Ethical statement. All studies were carried out in accordance with the guidelines of, and approved by, the Institutional Animal Care and Use Committee at the U.S. EPA’s National Health and Environmental Effects Research Laboratory.

Experimental design. We have previously shown the Spontaneously Hypertensive Rat (SHR) model to be more sensitive to diesel exhaust (DE) exposure than their normotensive counterparts. We designed our current study to include two primary cohorts of SHRs (Fig. 1):
Blood Collection Cohort. SHRs were grouped into low or high concentration DE groups or a filtered air control group and underwent terminal blood collection one hour after exposure. Serum was isolated from the collected blood, which was used for two purposes:

a. Rat aortic endothelial cells were cultured for 24 hours in media containing the serum (diluted to 10% in media) followed by subsequent testing of various in vitro markers of exposure

b. Proteomic characterization

Left Ventricular Pressure (LVP) Cohort. SHRs underwent LVP assessments one day after exposure to low or high concentrations of DE or filtered air.

Sample size analysis. The sample size analysis for this study was based on our previous study of DE exposure in heart failure prone rats in which we found that heart rates were different during exercise recovery. In that study the effect size (d) was about 35 beats/minute with a SD in heart rate of approximately 20 beats/minute. Based on Cohen’s sample size calculations for effect size index (f = 0.85 d/SD) we calculated f = 0.875. Sample size analysis was conducted using R Studio software (version 3.1.2) with the ‘pwr’ package and ‘pwr.anova.test’ command. We set k = 3 for our two DE groups and 1 control group, f = 0.875, significance level = 0.05, power = 0.8, and solved for n. This yielded n = 5.33 so we set n = 6 for the study.

Animals. We utilized two cohorts of SHRs (for LVP assessment and blood collection) each with 3 experimental groups containing 6 SHRs per group. Thus, thirty-six, 12-week old male SHRs were purchased from Charles River (SHR/NCrI, Strain Code 007, Raleigh, NC, USA). SHRs acclimated for at least one week in our Association for Assessment and Accreditation of Laboratory Animal Care-approved facility prior to any experimentation. They were housed in plastic cages (2/cage) and maintained on a 12-hour light/dark cycles at approximately 22 ± 1 °C and 50% relative humidity (RH). Food (Prolab RMH 3000; PMI Nutrition International, St Louis, MO) and water were provided ad libitum.

Diesel exhaust exposure. SHRs were exposed to either FA, DE150, or DE500 for 4-hours, as previously described. In short, DE originated from a single-cylinder 0.320L displacement Yanmar L70 V diesel generator operated at 3600 rpm on low sulfur diesel fuel (16 ppm) at a 3-kW load and was delivered with high efficiency particulate air (HEPA)-filtered room air and delivered to exposure chambers. The FA group was exposed to HEPA-filtered room air in a separate exposure chamber. DE contained ultrafine mode PM and NO2 concentrations comparable to observations in United States and European traffic tunnels and roadways.

Left ventricular pressure 24-hours after exposure. One day after exposures, SHRs were anesthetized with urethane (1.5 mg/kg i.p., Sigma) and prepared for LVP measurement by right carotid arterial catheterization with a 2-French transducer (SPR-320, Millar Instruments, Houston, TX). The left jugular vein was cannulated for cardiac stress test by sympathomimetic infusion (dobutamine HCl). The pressure transducer was calibrated using a Pressure Control Unit (Model 2000, Millar Instruments) and connected to a data acquisition interface (Powerlab 4/30, ADInstruments, Dunedin, New Zealand) and computer recording data at 1000 Hz sample rate. The probe was advanced into the LV and subjects were allowed to rest for 3–5 minutes before making a 2-minute baseline recording. Then freshly diluted dobutamine HCl (dissolved in 0.9% NaCl saline at 640 µg/mL) was i.v. infused for 2 minutes at a dose of 10 µg/kg/minute (Dob10). Subjects were allowed to recover until heart rate stabilized. Then an additional 2-minute baseline was recorded before administering 20 µg/kg/minute i.v. infusion for two minutes (Dob20). Acquisition software (LabChart Pro version 7.3.2, AD Instruments) generated heart rate (BPM), double product (systolic mmHg • dP/dT; mmHg/sec), peak systolic pressure (mmHg), end diastolic pressure (mmHg), mean pressure (mmHg), and peak minimum pressure slope (−dP/dT; mmHg/sec), peak systolic pressure (mmHg), end diastolic pressure (mmHg), mean pressure (mmHg), and double product (systolic mmHg • BPM) from the LVP tracing. LVP data were noted at the end of each baseline period, at peak response for Dob10 and Dob20, and at two minutes of recovery for comparison across groups. One subject was lost in the DE150 group due to surgical complication, yielding n = 5; otherwise each group had n = 6.

Serum collection from SHRs one-hour after exposure. SHRs from the Blood Collection cohort were exposed to FA, DE150, or DE500 (n = 6/group) and then anesthetized with sodium pentobarbital (100 mg/kg i.p.), one hour after exposure. Once unresponsive, SHRs underwent laparotomy and 7 to 10 mL of blood was collected from the abdominal aorta using a 20-gauge needle and syringe. Blood was centrifuged at 4 °C centrifuge for 10 minutes at 1500 rpm in serum separator tubes. Serum was then immediately collected, snap frozen, and stored at −80 °C until ready for in vitro experiments and proteomic assessment.

Cytotoxicity assay in rat aortic endothelial cells treated with serum from exposed SHRs. Cytotoxicity was evaluated with a 96-well plate MTS assay (Promega, Madison, WI). To do so, RAECs (ATCC, Manassas, VA) were grown to 90% confluency in 96-well plates. Rat serum collected from the Blood Collection cohort, 1-hour after exposure was diluted to 10% in cell culture media and added to RAECs for 24 hours in triplicate (n = 6). After serum treatment, media was removed, and the MTS assay was performed. Absorbance was read at 490 nm on a spectrophotometer (BioTek Synergy HT, BioTek, Winooski, VT). Each sample triplicate was averaged, divided by the average absorbance from the FA group (n = 6), and multiplied by 100 to yield percent viability compared to FA (n = 6 data points/group).
Nitric oxide synthase activity in rat aortic endothelial cells treated with serum from exposed SHRsa. NOS activity was evaluated using a 96-well plate absorbance assay (#NB78, Oxford Biomedical Research®). First, RAECs were grown to confluency in 24-well plates. Rat serum collected from the Blood Collection cohort 1-hour after exposure was diluted to 10% in cell culture media and added to RAECs for 24 hours in individual wells (n = 6). Following treatment, the media containing rat serum was removed. Cells were detached with 250 µL of trypsin. Trypsin was neutralized with 250 µL of media containing fetal bovine serum. Samples were transferred to 1.5 mL tubes and then centrifuged at 1200 rpm for 5 minutes. Media was removed. The cell pellet was washed with PBS and then centrifuged again at 1200 rpm for 5 minutes. PBS was removed. Lysis buffer (50 µL) was added to resuspend the cell pellet. A Pierce BCA Protein Assay was run to determine protein concentration of each sample. Protein from each sample (50 µg) was plated in duplicate (n = 6) into a 96-well format NOS assay. The assay was performed according to manufacturer’s instructions and the resulting absorbance was read at 540 nm on a spectrophotometer (BioTek Synergy HT, BioTek, Winooksi, VT). The absorbance average from the assay blanks was subtracted from all samples and standards. The NO concentrations for each sample well were calculated based on the assay standard curve. All duplicate NO concentration values were averaged, divided by the average NO concentration value for the FA group (n = 6), and multiplied by 100 to yield percent NO produced compared to FA (n = 6 data points/group).

RT-PCR of biomarkers in rat aortic endothelial cells treated with serum from exposed SHRsb. Expression of Alox15, Tbxas, Edn1, Ho1, Il33, Nos3, Icam1, Vcam1, Cxcl2, and Il6 mRNA were assessed in RAECs treated for 24 hours with serum collected from exposed SHRs. See Supplemental Material for details.

Assessment of 15-HETE in serum collected from exposed SHRsc. 15-HETE was extracted from serum samples and analyzed by ELISA (ADI-900–051, Enzo Life Sciences, Inc., Farmingdale, NY, USA). See Supplemental Material for details.

Vascular cell adhesion molecule-1 expression in rat aortic endothelial cells treated with serum from exposed SHRsd. VCAM-1 expression was determined by flow cytometry. First, RAECs were grown to 90% confluency in 96-well plates. Rat serum collected from the Blood Collection cohort, 1-hour after exposure was diluted to 10% in cell culture media and added to RAECs for 3 hours (n = 6/serum sample). Following the 3-hour treatment, cells were collected, washed with PBS, and fixed with 2% paraformaldehyde. After undergoing a PBS wash, cells were incubated for 30 min with a VCAM-1 antibody (1:200) (Cat# 13-1060-81, eBioscience, San Diego, CA) followed by the incubation for 30 min with FITC-labeled streptavidin (1:200) (Cat# 11-4317-87, eBioscience) at room temperature. Cells were then washed with PBS and resuspended in 200 µL prior to evaluation by flow cytometry (Accuri C6 Flow Cytometer, BD Biosciences, San Jose, CA). Control cells not exposed to rat serum were similarly processed but did not receive the primary VCAM-1 antibody, only the secondary. This sample was utilized to subtract background binding by the secondary antibody. 10,000 events were analyzed for each sample and measuring mean fluorescence. The mean fluorescence reported for the “no stain” (no primary) controls for each sample were subtracted from all mean fluorescence values for the stained samples. The resulting data values for each sample were divided by mean value for the FA group (n = 6) and then multiplied by 100 to yield percent VCAM-1 expression compared to FA (n = 6 data points/group).

Sample preparation for serum proteomic analysis. For a more detailed description of proteomic assessments, see the Supplemental Materials. In short, rat serum that was collected from the Blood Collection Cohort, 1-hour after exposure and frozen. Prior to assessment, serum was thawed, diluted 5-fold and filtered at 0.22 µm to remove particulates. Samples were depleted of highly abundant proteins albumin, IgG, and transferrin using a Multiple Affinity Removal Column (Agilent Technologies, Santa Clara, CA, USA) to allow for quantification of the lower abundance proteins. The resultant flow-through fraction was trypsin-digested overnight using a modified Filter Aided Sample Preparation method. A Pierce™ BCA assay kit (Thermo Fisher Scientific, Waltham, MA, USA) was used per the manufacturer’s instructions for the enhanced assay to measure the protein concentration of each low-abundant protein fraction. Peptides were fractionated by high pH fractionation using an offline 1200 series Agilent HPLC system. The resulting fractions were analyzed by LCMS/MS on an Agilent 6520 QTOF. Data were collected in positive ion polarity over mass ranges 100–2200 m/z at a scan rate of 3 spectra/second.

Serum proteomic analysis. Identified spectra were used to populate an accurate mass and time (AMRT) database. Unfractionated digested rat serum samples were analyzed by LCMS for differential analysis. Peptides which passed differential filters (ANOVA and fold change, see Statistics section) were identified in one of two ways: differential peptides were used to search the AMRT database. The remaining peptides without database hits were then targeted for by LCMS/MS and the resulting spectra were searched against the SwissProt Rattus Norvegicus database in Spectrum Mill (Agilent, Santa Clara, CA) allowing up to 2 missed tryptic cleavages with variable carbamidomethyl (C), deamidated (N), oxidation (M), N-term pyroglutamic acid (Q), and phosphorylated (STY) modifications. Data was extracted and aligned for mass and time using a recursive strategy performed in Profinder software (Agilent) and Mass Profiler Professional software (Agilent). Peptides were annotated using ID Browser software (Agilent) by matching mass and retention time from aligned experimental data to peptide entries in the AMRT library generated previously from MS/MS data. The annotated peptide list was filtered to peptides that were found in at least 4 of 6 samples and in at least 1 of 3 conditions. Peptides were rolled up into protein abundances using sort and subtotal functions within Microsoft Excel.
**Statistical analyses.** Biological data are reported as mean ± SD (or SEM for clarity in Fig. 2) or presented as boxplots with all data points shown. Box edges identify the interquartile range, the middle line identifies the median, the “*” identifies the mean, and the whiskers identify the minimum and maximum data values. Data were analyzed and graphed with Graphpad Prism 6 software version 6.07 (La Jolla, CA, USA). In Fig. 2, LVP data are mean ± SEM for improved clarity (n = 6/group). These data were analyzed by two-way repeated measures ANOVA across exposure groups, with Tukey’s multiple comparisons test and multiplicity adjusted p-values; *denotes p < 0.05 between FA and DE500; †denotes p < 0.05 between FA and DE150. In Figs 3 and 4, normalized LVP data and endothelial bioactivity data were analyzed by one-way ANOVA across exposure groups, with Tukey’s multiple comparisons test and multiplicity adjusted p-values, and by one-way ANOVA across exposure groups with linear trend analyses for multiple comparisons; *denotes p < 0.05 vs. FA; †denotes p < 0.05 vs. DE150; ‡denotes p < 0.05 for linear trend. In Table 2, animal weight data were analyzed by two-way ANOVA across cohort (LVP vs. Blood Collection) within exposure group, with Bonferroni’s multiple comparisons test and multiplicity adjusted p-values; data were also analyzed by two-way ANOVA across exposure group within cohort, with Tukey’s multiple comparisons test and multiplicity adjusted p-values. In Table 3, LVP data were analyzed by one-way ANOVA across exposure groups, with Tukey’s multiple comparisons test and multiplicity adjusted p-values: *denotes p < 0.05 vs. FA; †denotes p < 0.05 vs. DE150. To assess LVP parameter responsiveness and stability during dobutamine challenge and recovery, data were also analyzed by two-way repeated measures ANOVA across time point within each exposure group, with Tukey’s multiple comparisons test and multiplicity adjusted p-values: †denotes p < 0.05 for an increase from the previous time point; ‡denotes p < 0.05 for a decrease from the previous time point. Serum protein abundance values were imported into Mass Profiler Professional software (Agilent Technologies) for statistical analysis. In Table 4, protein significance was determined using a moderated t-test between combinations of the 3 groups: DE500 vs. FA, DE500 vs. FA, DE500 vs. FA. When protein changes were 20% or greater. In Table 5, a one-way ANOVA with Tukey’s post-test was used on all 3 groups. Proteins were considered significant if changes produced p < 0.05. Further details regarding statistical analysis of proteomic data can be found within the Supplemental Material. For Fig. 5, peptides that passed a one-way ANOVA significance test (p < 0.05) with a Benjamini Hochberg multiple testing correction were clustered using unsupervised hierarchical clustering using the Euclidian distance metric and Ward’s linkage rule⁶.

**Data Availability** All data generated or analyzed during this study are included in this published article [and its Supplementary Information Files].

**References**

1. Bind, M. A. *et al.* Quantile Regression Analysis of the Distributional Effects of Air Pollution on Blood Pressure, Heart Rate Variability, Blood Lipids, and Biomarkers of Inflammation in Elderly American Men: The Normative Aging Study. *Environmental health perspectives* 124, 1189–1198, https://doi.org/10.1289/ehp.1510044 (2016).

2. Bower, J. R. *et al.* Metabolic changes in murine serum following inhalation exposure to gasoline and diesel engine emissions. *Inhalation toxicology* 28, 241–250, https://doi.org/10.3109/08958378.2016.1155003 (2016).

3. Nemmar, A. *et al.* Diesel Exhaust Particles Induce Impairment of Vascular and Cardiac Homeostasis in Mice: Ameliorative Effect of Emodin. *Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology* 36, 1517–1526, https://doi.org/10.1159/000430315 (2015).

4. Pila, V. *et al.* C-reactive protein (CRP) and long-term air pollution with a focus on ultrafine particles. *International journal of hygiene and environmental health* 221, 510–518, https://doi.org/10.1016/j.ijheh.2018.01.016 (2018).

5. Siponen, T. *et al.* Source-specific fine particulate air pollution and systemic inflammation in ischaemic heart disease patients. *Occupational and environmental medicine* 72, 277–283, https://doi.org/10.1136/oemed-2014-102240 (2015).

6. Chen, M. *et al.* Concentrated Ambient PM2.5-Induced Inflammation and Endothelial Dysfunction in a Murine Model of Neural IKK2 Deficiency. *Environmental health perspectives* 126, 027003, https://doi.org/10.1289/ehp.2111 (2016).

7. Gorr, M. W., Falvo, M. J. & Wold, L. E. Air Pollution and Other Environmental Modulators of Cardiac Function. *Comprehensive Physiology* 7, 1479–1495, https://doi.org/10.1002/cphy.c170017 (2017).

8. Liu, C. W. *et al.* PM2.5-induced oxidative stress increases intercellular adhesion molecule-1 expression in lung epithelial cells through the IL-6/STAT3/NF-kappaB-dependent pathway. *Particle and fibre toxicology* 15, 4, https://doi.org/10.1186/s12989-018-0240-x (2018).

9. Wang, J. *et al.* Urban particulate matter triggers lung inflammation via the ROS-MAPK-NF-kappaB signaling pathway. *Journal of thoracic disease* 9, 4398–4412, https://doi.org/10.21037/jtd.2017.09.135 (2017).

10. Yan, Z. *et al.* Inflammatory cell signaling following exposures to particulate matter and ozone. *Biochimica et biophysica acta* 1860, 2826–2834, https://doi.org/10.1016/j.bbadis.2016.03.030 (2016).

11. Channell, M. M., Puffett, M. L., Devin, R. B., Madden, M. C. & Campen, M. J. Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: evidence from a novel translational in vitro model. *Toxicological sciences: an official journal of the Society of Toxicology* 127, 179–186, https://doi.org/10.1093/toxsci/kfs084 (2012).

12. Aragon, M. J. *et al.* Inflammatory and Vasoactive Effects of Serum Following Inhalation of Varied Complex Mixtures. *Cardiovascular toxicology* 16, 163–171, https://doi.org/10.1007/s12012-015-9325-z (2016).

13. Hazari, M. S., Lancaster, J. L., Starobin, J. M., Farraj, A. K. & Cascio, W. E. Diesel Exhaust Worsens Cardiac Conduction Instability in Dobutamine-Challenged Wistar-Kyoto and Spontaneously Hypertensive Rats. *Cardiovascular toxicology* 17, 120–129, https://doi.org/10.1007/s12012-016-9366-0 (2017).

14. Hazari, M. S. *et al.* Dobutamine “stress” test and latent cardiac susceptibility to inhaled diesel exhaust in normal and hypertensive rats. *Environmental health perspectives* 120, 1088–1093, https://doi.org/10.1289/ehp.1104684 (2012).

15. Yamori, Y. *et al.* Cardiac hypertrophy in early hypertension. *Am J Cardio* 44, 964–969 (1979).

16. Liu, S. V., Chen, F. L. & Xue, J. Evaluation of Traffic Density Parameters as an Indicator of Vehicle Emission-Related Near-Road Air Pollution: A Case Study with NEXUS Measurement Data on Black Carbon. *International journal of environmental research and public health* 14, https://doi.org/10.3390/ijerph141121581 (2017).

17. Li, D. *et al.* Characterization and source identification of fine particulate matter in urban Beijing during the 2015 Spring Festival. *The Science of the total environment* 628–629, 430–440, https://doi.org/10.1016/j.scitotenv.2018.01.304 (2018).
18. Coble, J. B. et al. The Diesel Exhaust in Miners Study: II. Exposure monitoring surveys and development of exposure groups. The Annals of occupational hygiene 54, 747–761, https://doi.org/10.1093/annhyg/meq024 (2010).

19. Karthikeyan, S. et al. Nitrogen dioxide and ultrafine particles dominate the biological effects of inhaled diesel exhaust treated by a catalyzed diesel particulate filter. Toxicological sciences: an official journal of the Society of Toxicology 135, 437–450, https://doi.org/10.1093/toxsci/kft162 (2013).

20. Endemann, D. H. & Schiffrin, E. L. Endothelial dysfunction. Journal of the American Society of Nephrology: JASN 15, 1833–1992, https://doi.org/10.1097/01.asn.0000132474.50966.da (2004).

21. Flammer, A. J. et al. The assessment of endothelial function: from research into clinical practice. Circulation 126, 753–767, https://doi.org/10.1161/circulationaha.112.039245 (2012).

22. Carl, A. P. et al. An autonomic link between inhaled diesel exhaust and impaired cardiac performance: insight from treadmill and dobutamine challenges in heart failure-prone rats. Toxicological sciences: an official journal of the Society of Toxicology 135, 425–436, https://doi.org/10.1093/toxsci/kft155 (2013).

23. Priép, R. C. et al. Dobutamine antagonizes epinephrine's biochemical and cardiotoxic effects: results of an in vitro model using human lymphocytes and a clinical study in patients recovering from cardiac surgery. Anesthesiology 89, 49–57 (1998).

24. Volpino, P. et al. Respiratory and cardiovascular function at rest and during exercise testing in a healthy working population: effects of outdoor traffic air pollution. Occupational medicine (Oxford, England) 54, 475–482, https://doi.org/10.1093/occmed/kqh102 (2004).

25. Amsterdam, E. A. & Mason, D. T. Exercise testing and indirect assessment of myocardial oxygen consumption in evaluation of angina pectoris. Cardiology 62, 174–189, https://doi.org/10.1159/000169852 (1977).

26. Koene, R. J., Adkison, W. O. & Bendift, D. G. Syncope and the risk of sudden cardiac death: Evaluation, management, and prevention. Journal of arrhythmia 33, 533–544, https://doi.org/10.1016/j.joa.2017.07.005 (2017).

27. Legramante, J. M. et al. Hemodynamic and autonomic correlates of postexercise hypotension in patients with mild hypertension. American journal of physiology. Regulatory, integrative and comparative physiology 282, R1037–R1043, https://doi.org/10.1152/ajpregu.00603.2001 (2002).

28. Hazari, M. S. et al. A single exposure to acrolein desensitizes baroreflex responsiveness and increases cardiac arrhythmias in normotensive and hypertensive rats. Cardiovascular toxicology 14, 52–63, https://doi.org/10.1007/s12012-013-9228-9 (2014).

29. Highton, P. J., Martin, N., Smith, A. C., Burton, J. O. & Bishop, N. C. Microparticles and Exercise in Clinical Populations. Proceedings of the Royal Society of London. Series B, Biological Sciences 279, 3205–3212, https://doi.org/10.1098/rspb.2012.2795 (2012).

30. Sheng, Y. & Zhu, L. The crosstalk between autonomic nervous system and blood vessels. Regulatory, integrative and comparative physiology 10, 17–28 (2018).

31. Cherng, T. W. et al. Mechanisms of diesel-induced endothelial nitric oxide synthase dysfunction in coronary arterioles. Environmental health perspectives 119, 98–103, https://doi.org/10.1289/ehp.1002286 (2011).

32. Cheng, T. W., Campen, M. J., Knuckles, T. L., Gonzalez Bosc, L. & Kanagy, N. L. Impairment of coronary endothelial cell ET(B) receptor function after short-term inhalation exposure to whole diesel emissions. American journal of physiology. Regulatory, integrative and comparative physiology 297, R640–647, https://doi.org/10.1152/ajpregu.00889.2008 (2009).

33. Sun, Y., Taguchi, K., Sumi, D., Yamano, S. & Kumagai, Y. Inhibition of endothelial nitric oxide synthase activity and suppression of endothelium-dependent vasorelaxation by 1,2-naphthoquinone, a component of diesel exhaust particles. Archives of toxicology 80, 280–285, https://doi.org/10.1007/s00204-005-0043-3 (2006).

34. Kumagai, Y. et al. Phenanthraquinone inhibits eNOS activity and suppresses vasorelaxation. American journal of physiology. Regulatory, integrative and comparative physiology 281, R23–30, https://doi.org/10.1152/ajpregu.2001.281.1.R23 (2001).

35. Khan, B. V., Harrison, D. G., Olbrych, M. T., Alexander, R. W. & Medford, R. M. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 93, 9114–9119 (1996).

36. Bengall, R. et al. The role of IL-6 released from pulmonary epithelial cells in diesel UFP-induced endothelial activation. Environmental pollution (Barking, Essex: 1987) 135, 1277–1285 (2005).

37. Krishnan, R. M. et al. A randomized cross-over study of inhalation of diesel exhaust, hematological indices, and endothelial markers in humans. Particle and fibre toxicology 10, 7, https://doi.org/10.1186/1743-8977-10-7 (2013).

38. Efendiev, R. & Dessauer, C. W. A kinase-anchoring proteins and adenyl cyclase in cardiovascular physiology and pathology. Journal of cardiovascular pharmacology 58, 339–344, https://doi.org/10.1097/FJC.0b013e31821bc3b0 (2011).

39. Je, W. et al. Pathophysiologic Functions of Rnd3/RhoE. Comprehensive Physiology 6, 169–186, https://doi.org/10.1002/cphy.c150018 (2015).

40. Tseng, C. Y., Wang, J. S. & Chao, M. W. Causation by Diesel Exhaust Particles of Endothelial Dysfunctions in Cytotoxicity, Pro-inflammation, Permeability, and Apoptosis Induced by ROS Generation. Cardiovascular toxicology 17, 384–392, https://doi.org/10.1007/s10126-012-9364-0 (2017).

41. Rulkind, J. M., Mohanty, J. G. & Nagabahu, E. The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions. Frontiers in physiology 5, 500, https://doi.org/10.3389/fphys.2014.00500 (2014).

42. Hansson, S. R., Naav, A. & Erlandsson, L. Oxidative stress in preeclampsia and the role of free fetal hemoglobin. Frontiers in physiology 5, 516, https://doi.org/10.3389/fphys.2014.00516 (2014).

43. Bellini, S. et al. Heat Shock Proteins in Vascular Diabetic Complications: Review and Future Perspective. International journal of molecular sciences 18, 11987, https://doi.org/10.3390/ijms181211987 (2017).

44. Armutcu, F., Ataymen, M., Atmaca, H. & Gurel, A. Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clinical chemistry and laboratory medicine 46, 785–790, https://doi.org/10.1515/cclm.2008.166 (2008).

45. Bresnahan, K. A. & Tanumihardjo, S. A. Antioxidant, the acute phase reaction to infection, and its effects on micronutrient status indicators. Advances in nutrition (Bethesda, Md.) 5, 702–711, https://doi.org/10.3945/an.114.006361 (2014).
54. Horne, B. D. et al. Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection. *American journal of respiratory and critical care medicine* **198**, 759–766, https://doi.org/10.1164/ajrccm.201709-1883OC (2018).

55. Gambone, L. M., Fujitawa, Y. & Murray, P. A. Endothelium-dependent pulmonary vasodilation is selectively attenuated during isoflurane anesthesia. *The American journal of physiology* **272**, H290–298, https://doi.org/10.1152/ajpheart.1997.272.1.H290 (1997).

56. Thompson, J. S. et al. Early effects of tribromoethanol, ketamine/xylazine, pentobarbital, and isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice. *Comparative medicine* **52**, 63–67 (2002).

57. Kapur, S. et al. Early development of intracellular calcium cycling defects in intact hearts of spontaneously hypertensive rats. *American journal of physiology. Heart and circulatory physiology* **299**, H1843–1853, https://doi.org/10.1152/ajpheart.00623.2010 (2010).

58. Cohen, J. A power primer. *Psychological bulletin* **112**, 155–159 (1992).

59. Carll, A. P. et al. Whole and particle-free diesel exhausts differentially affect cardiac electrophysiology, blood pressure, and autonomic balance in heart failure-prone rats. *Toxicological sciences: an official journal of the Society of Toxicology* **128**, 490–499, https://doi.org/10.1093/toxsci/kfs162 (2012).

60. Anselme, F. et al. Inhalation of diluted diesel engine emission impacts heart rate variability and arrhythmia occurrence in a rat model of chronic ischemic heart failure. *Archives of toxicology* **81**, 299–307, https://doi.org/10.1007/s00204-006-0147-4 (2007).

61. Svartengren, M., Strand, V., Bylin, G., Jarup, L. & Pershagen, G. Short-term exposure to air pollution in a road tunnel enhances the asthmatic response to allergen. *The European respiratory journal* **15**, 716–724 (2000).

62. Zhu, Y., Figueroa-Fernandez, A., Hinds, W. C. & Miguel, A. H. In-cabin commuter exposure to ultrafine particles on Los Angeles freeways. *Environmental science & technology* **41**, 2138–2145 (2007).

63. Legg, K. M., Powell, R., Reisdorph, N., Reisdorph, R. & Danielson, P. B. Discovery of highly specific protein markers for the identification of biological stains. *Electrophoresis* **35**, 3069–3078, https://doi.org/10.1002/elps.201400125 (2014).

64. Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. *Molecular & cellular proteomics: MCP* **1**, 845–867 (2002).

65. Issaq, H. J., Xiao, Z. & Veenstra, T. D. Serum and plasma proteomics. *Chemical reviews* **107**, 3601–3620, https://doi.org/10.1021/cr068287r (2007).

66. Key, M. A tutorial in displaying mass spectrometry-based proteomic data using heat maps. *BMC bioinformatics* **13**(Suppl 16), S10, https://doi.org/10.1186/1471-2105-13-s16-s10 (2012).

**Acknowledgements**

This work was funded by the intramural research program of the Office of Research and Development, U.S. Environmental Protection Agency, and by the National Institutes of Health grants RO1 ES019311 (J.M.B.) and K99 ES024392 (J.H.S.). We would like to thank following: Dr. Nichole Reisdorph, Dr. Richard Reisdorph, and Cole Michel of the University of Colorado, Anschutz Medical Campus, School of Pharmacy Mass Spectrometry Facility Core; Molly Windsor of SRA International, Inc. for producing the experimental design graphic in Fig. I; and Dr. Barbara Buckley and Dr. M. Ian Gilmour of the U.S. EPA for their thorough review of this manuscript. The research presented in the article was reviewed and approved for publication by the National Health and Environmental Effects Research Laboratory at the U.S. Environmental Protection Agency. The contents of this manuscript do not necessarily reflect the views and policies of the agency nor does mention of trade names or commercial products signify endorsement or recommendation for use.

**Author Contributions**

L.C.T. analyzed in vivo physiology data, interpreted physiology data, and was co-lead author of the manuscript. J.H.S. collected, analyzed, and interpreted in vitro and proteomic data, and was co-lead author of the manuscript. C.M.P., A.K.F. and M.S.H. carried out in vivo exposures and physiology data collection. N.H.C. provided technical assistance with in vitro exposures and serum collection. C.K. was the exposure facility engineer for the DE exposures and collected exposure data. J.M.B. provided oversight for all in vitro and proteomic data collection and analyses. J.M.B. and A.K.F. were involved in all aspects of the study including manuscript preparation.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-019-43339-8.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2019